Could a weekly pill prevent TB in kids with HIV?

NCT ID NCT05122767

Ongoing Disease control Sponsor: The Aurum Institute NPC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a once-weekly combination of two drugs (rifapentine and isoniazid) can safely prevent tuberculosis in children and teens with HIV who are already taking the antiretroviral dolutegravir. About 92 participants aged 3 months to 17 years will receive the TB prevention for 12 weeks. Researchers will check for drug interactions and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rifapentine and isoniazid (3HP) plus dolutegravir
What this could lead to: If successful, this could provide a safe, short-course option to prevent tuberculosis in children with HIV who are on modern antiretroviral therapy.
What could go wrong: This is an early-phase (1/2) trial with only 92 participants, so results may not apply broadly. Drug interactions or side effects could still arise.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease latent tuberculosis infection tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV TUBERCULOSIS

Contacts and locations

Locations

Peri Natal HIV Research Unit - Klerksdorp Tshepong Hospital

Klerksdorp, North West, 2571, South Africa
The Aurum Institute: Pretoria Clinical Research Centre

Pretoria, Gauteng, 0087, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.